Substantial Global Turnover Reflects Current Healthy Market

A growth rate averaging 18% per annum over the last ten years, which more than doubled in the past two years, has been reported by INTEGA Biosciences. In 2020 the company grew by 73%, followed by a 46% increase in turnover in 2021, reaching 191 million Swiss Francs.

Describing the life sciences industry as 'thriving' and currently experiencing unprecedented demand for liquid handling solutions, INTEGA’s portfolio of pipettes - including the recently launched MINI 96, a 96 channel portable electronic pipette - are helping to drive the company’s continued expansion. Having attracted a further 1000 new customers in 2021, the company hired an additional 100 employees to increase its global operating capacity. Similar results are expected in 2022, with the company forecasting double-figure growth. This is likely to be driven by an increase in direct sales in multiple countries across Asia and Europe, as well as being supported by new product launches. The recently announced construction of a new office and production building - the INTEGRA Campus - will continue at Zizers and another 150 staff are planned to be employed across various sectors globally.   

Chief Executive Officer Urs Hartman said: “Our innovative solutions make for a reliable partner in the lab and 99% of our customers say that they would continue to use, and recommend, INTEGRA products. Creating a positive and safe working environment for our staff is crucial to the company’s success, together with ensuring that growth doesn’t compromise our long-term sustainability objectives.”

More information online